Imagine the life of a yeast cell, floating around the kitchen in a spore that eventually lands on a bowl of grapes. Life is good: food for days, at least until someone notices the rotting fruit and throws them out.
Updated: Pfizer abandons twice-daily GLP-1 approach due to high discontinuation rates, goes back to PhI with once-a-day dose
Pfizer won’t be moving a twice-daily formulation of its oral GLP-1, danuglipron, into Phase III after the drug triggered high rates of gastrointestinal side effects,
December 2, 2023